Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 12

Results For "EPS"

550 News Found

Promotion of indigenous pharmaceutical manufacturing
Policy | December 04, 2025

Promotion of indigenous pharmaceutical manufacturing

PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore


Amrutanjan re-launches its iconic yellow balm
News | November 29, 2025

Amrutanjan re-launches its iconic yellow balm

Amrutanjan is also rolling out its new campaign, 'Har Dard Mitaye'


India’s pharma industry showcases innovation, global ambitions at CPHI & PMEC India 2025
News | November 27, 2025

India’s pharma industry showcases innovation, global ambitions at CPHI & PMEC India 2025

India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem


Dr. Lal PathLabs launches India's first complement testing lab
News | November 27, 2025

Dr. Lal PathLabs launches India's first complement testing lab

The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards


Telangana fires up biologics innovation, debuts India's first single-use bioprocess scale-up hub
R&D | November 25, 2025

Telangana fires up biologics innovation, debuts India's first single-use bioprocess scale-up hub

The State’s PPP model has already mobilised Rs. 150 crore in core infrastructure, while Thermo Fisher has invested Rs. 90 crore in the Bioprocess Design Centre and its co-located Customer Experience Centre


Solventum to acquire Acera Surgical in $725 million deal
News | November 25, 2025

Solventum to acquire Acera Surgical in $725 million deal

Solventum aims to accelerate innovation in acute wound care, expand its market reach, and deliver enhanced solutions for patients, clinicians, and shareholders


FDA approves combo therapy for Cisplatin-ineligible muscle-invasive bladder cancer patients
Drug Approval | November 23, 2025

FDA approves combo therapy for Cisplatin-ineligible muscle-invasive bladder cancer patients

The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy